Menu Search
Equities

Ironwood Pharmaceuticals Inc

IRWD:NSQ

Ironwood Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.40
  • Today's Change-0.385 / -8.05%
  • Shares traded1.58m
  • 1 Year change-54.88%
  • Beta0.4975
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ironwood Pharmaceuticals Inc had net income fall from a gain of 175.07m to a loss of 1.00bn despite a 7.83% increase in revenues from 410.60m to 442.74m. An increase in the selling, general and administrative costs as a percentage of sales from 28.25% to 35.76% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin-0.82%
Operating margin26.22%
Return on assets-0.68%
Return on equity--
Return on investment-1.07%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Ironwood Pharmaceuticals Inc fell by 565.78m. Cash Flow from Financing totalled 277.16m or 62.60% of revenues. In addition the company generated 183.43m in cash from operations while cash used for investing totalled 1.03bn.
Cash flow per share-0.0068
Price/Cash flow per share--
Book value per share-1.95
Tangible book value per share-1.96
More ▼

Balance sheet in USDView more

Ironwood Pharmaceuticals Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, although this company's debt load outweighs its assets, its Interest Coverage ratio, at 63.787799999999997, shows that it is comfortably able to pay interest expenses out of operating profits.
Current ratio3.62
Quick ratio--
Total debt/total equity--
Total debt/total capital2.08
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -769.22%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		99.74
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.